- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/61 - Growth hormone [GH], i.e. somatotropin
Patent holdings for IPC class C07K 14/61
Total number of patents in this class: 317
10-year publication summary
28
|
23
|
35
|
25
|
28
|
22
|
19
|
25
|
10
|
11
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Opko Biologics Ltd. | 77 |
31 |
Modernatx, Inc. | 1283 |
10 |
Novo Nordisk Health Care AG | 336 |
8 |
Amunix Pharmaceuticals, Inc. | 81 |
8 |
Ubiprotein, Corp. | 12 |
8 |
JCR Pharmaceuticals Co., Ltd. | 221 |
7 |
Molecular Technologies Laboratories LLC | 11 |
7 |
Novocodex Biopharmaceuticals Co., Ltd. | 14 |
7 |
Massachusetts Institute of Technology | 10115 |
6 |
Alteogen Inc. | 65 |
6 |
Asterion Limited | 23 |
6 |
Ambrx, Inc. | 183 |
5 |
The Scripps Research Institute | 1347 |
5 |
Novo Nordisk A/S | 2281 |
5 |
Ascendis Pharma Endocrinology Division A/S | 60 |
5 |
Lateral IP Pty Ltd | 19 |
5 |
Duke University | 3090 |
4 |
Ohio University | 367 |
4 |
Translate bio, Inc. | 416 |
4 |
Prevail Therapeutics, Inc. | 67 |
4 |
Other owners | 172 |